Quick Answer
ALX ONCOLOGY HOLDINGS INC reported R&D Expense of $77.00 million for fiscal year 2025.
ALX ONCOLOGY HOLDINGS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $77.00M | -33.8% |
| 2024 | $116.37M | -17.9% |
| 2023 | $141.79M | +44.1% |
| 2022 | $98.40M | +63.5% |
| 2021 | $60.17M | +107.8% |
| 2020 | $28.96M | +77.6% |
| 2019 | $16.31M | +44.7% |
| 2018 | $11.27M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.44M | -34.1% | -3.2% |
| June 30, 2025 | $18.02M | -48.0% | -24.6% |
| March 31, 2025 | $23.89M | -24.7% | -9.8% |
| September 30, 2024 | $26.47M | -42.2% | -23.6% |
| June 30, 2024 | $34.65M | +17.5% | +9.3% |
| March 31, 2024 | $31.72M | +28.1% | -30.7% |
| September 30, 2023 | $45.77M | +55.8% | +55.2% |
| June 30, 2023 | $29.48M | +10.2% | +19.1% |
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -33.8% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, ALX ONCOLOGY HOLDINGS INC’s r&d expense has grown by 583.2% (from $11.27 million to $77.00 million).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: